Abstract
ObjectivesAtrial fibrillation (AF) is a heterogeneous condition. We performed a cluster analysis in a cohort of patients with AF and assessed the prognostic implication of the identified cluster phenotypes.MethodsWe used two multicentre, prospective, observational registries of AF: the SAKURA AF registry (Real World Survey of Atrial Fibrillation Patients Treated with Warfarin and Non-vitamin K Antagonist Oral Anticoagulants) (n=3055, derivation cohort) and the RAFFINE registry (Registry of Japanese Patients with Atrial Fibrillation Focused on anticoagulant therapy in New Era) (n=3852, validation cohort). Cluster analysis was performed by the K-prototype method with 14 clinical variables. The endpoints were all-cause mortality and composite cardiovascular events.ResultsThe analysis subclassified derivation cohort patients into five clusters. Cluster 1 (n=414, 13.6%) was characterised by younger men with a low prevalence of comorbidities; cluster 2 (n=1003, 32.8%) by a high prevalence of hypertension; cluster 3 (n=517, 16.9%) by older patients without hypertension; cluster 4 (n=652, 21.3%) by the oldest patients, who were mainly female and with a high prevalence of heart failure history; and cluster 5 (n=469, 15.3%) by older patients with high prevalence of diabetes and ischaemic heart disease. During follow-up, the risk of all-cause mortality and composite cardiovascular events increased across clusters (log-rank p<0.001, p<0.001). Similar results were found in the external validation cohort.ConclusionsMachine learning-based cluster analysis identified five different phenotypes of AF with unique clinical characteristics and different clinical outcomes. The use of these phenotypes may help identify high-risk patients with AF.
Funder
PARAMOUNT BED HOLDINGS CO., LTD.
Resmed Japan
Eisai Co., Ltd, Bayer Yakuhin, Ltd
Philips Japan Inc., FUJIFILM Holdings Corporation, Asahi Kasei Corp., Inter Reha Co. Ltd, Toho Holdings Co. Ltd
Bayer Yakuhin, Ltd
Medtronic Japan
Boston Scientific Japan, Abbott
Bayer Healthcare, Daiichi-Sankyo, Bristol
Bayer Healthcare, Daiichi-Sankyo
Fukuda Denshi Co. Ltd
Nippon Boehringer Ingelheim, Pfizer Japan
Squibb
Novartis Pharma
Boston Scientific Japan
Philips Japan Inc.
Subject
Cardiology and Cardiovascular Medicine